What does DUVAL PHARMACEUTICS CONSULTING do?

DUVAL PHARMACEUTICS CONSULTING is a healthcare practice in Zandhoven. Private Limited, started on 26 January 2005, 1 establishment.

What is the address of DUVAL PHARMACEUTICS CONSULTING?

The registered office of DUVAL PHARMACEUTICS CONSULTING is located at Schoolstraat 6, 2240 Zandhoven.

Is DUVAL PHARMACEUTICS CONSULTING still active?

Yes. According to the CBE (16 September 2026) DUVAL PHARMACEUTICS CONSULTING is active, legal situation “Normale toestand”, started on 26 January 2005.

Is DUVAL PHARMACEUTICS CONSULTING registered on Peppol?

Yes, DUVAL PHARMACEUTICS CONSULTING is registered on the Peppol network with ID 0208:0871467004.

What is the enterprise number of DUVAL PHARMACEUTICS CONSULTING?

The enterprise number of DUVAL PHARMACEUTICS CONSULTING is BE0871467004.

When was DUVAL PHARMACEUTICS CONSULTING founded?

DUVAL PHARMACEUTICS CONSULTING was founded on 26 January 2005.

Who are the directors of DUVAL PHARMACEUTICS CONSULTING?

According to the 2025 annual accounts, the directors of DUVAL PHARMACEUTICS CONSULTING are: Didier Duval.

Is DUVAL PHARMACEUTICS CONSULTING a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 January 2005; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DUVAL PHARMACEUTICS CONSULTING make in 2025?

DUVAL PHARMACEUTICS CONSULTING posted a profit after taxes of € 41,941 in financial year 2025.

What is the revenue of DUVAL PHARMACEUTICS CONSULTING?

As a small company, DUVAL PHARMACEUTICS CONSULTING is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 81,783.

DUVAL PHARMACEUTICS CONSULTING (Private Limited)

Dossier DUVAL PHARMACEUTICS CONSULTING, printed on 16 September 2026 from databakkes.be/en/0871467004/duval-pharmaceutics-consulting. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DUVAL PHARMACEUTICS CONSULTING from Zandhoven, company number BE0871467004, closed financial year 2025 with a result of € 41,941 after tax. For that financial year DUVAL PHARMACEUTICS CONSULTING recorded a gross margin of € 81,783 and equity of € 148,604. Compared with financial year 2024, the result moved from € 30,663 to € 41,941. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 29, 2026.

What it is worth Growing

€ 148,604

▲ 39% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 41,941

▲ 37% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 91,061

▲ 12% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 136,204.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 2,914

▼ 28% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 128

▼ 99% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 2,225

▼ 13% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 5,638

▼ 1% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 43,394 Gross margin 2022: € 43,394 First fiscal year in the series	€ 68,947 Gross margin 2023: € 68,947 ▲ 59% vs 2022 (€ 43,394) Favourable step	€ 72,215 Gross margin 2024: € 72,215 ▲ 5% vs 2023 (€ 68,947) Favourable step	€ 81,783 Gross margin 2025: € 81,783 ▲ 13% vs 2024 (€ 72,215) Favourable step	▲ 13%
Profit after taxes	€ 6,916 Profit after taxes 2022: € 6,916 First fiscal year in the series	€ 25,035 Profit after taxes 2023: € 25,035 ▲ 262% vs 2022 (€ 6,916) Favourable step	€ 30,663 Profit after taxes 2024: € 30,663 ▲ 22% vs 2023 (€ 25,035) Favourable step	€ 41,941 Profit after taxes 2025: € 41,941 ▲ 37% vs 2024 (€ 30,663) Favourable step	▲ 37%
Equity	€ 57,081 Equity 2022: € 57,081 First fiscal year in the series	€ 75,999 Equity 2023: € 75,999 ▲ 33% vs 2022 (€ 57,081) Favourable step	€ 106,662 Equity 2024: € 106,662 ▲ 40% vs 2023 (€ 75,999) Favourable step	€ 148,604 Equity 2025: € 148,604 ▲ 39% vs 2024 (€ 106,662) Favourable step	▲ 39%
Total debts	€ 73,631 Total debts 2022: € 73,631 First fiscal year in the series	€ 62,440 Total debts 2023: € 62,440 ▼ 15% vs 2022 (€ 73,631) Favourable step	€ 20,455 Total debts 2024: € 20,455 ▼ 67% vs 2023 (€ 62,440) Favourable step	€ 7,990 Total debts 2025: € 7,990 ▼ 61% vs 2024 (€ 20,455) Favourable step	▼ 61%
Cash	€ 48,614 Cash 2022: € 48,614 First fiscal year in the series	€ 67,643 Cash 2023: € 67,643 ▲ 39% vs 2022 (€ 48,614) Favourable step	€ 81,286 Cash 2024: € 81,286 ▲ 20% vs 2023 (€ 67,643) Favourable step	€ 91,061 Cash 2025: € 91,061 ▲ 12% vs 2024 (€ 81,286) Favourable step	▲ 12%
Retained profit	€ 44,681 Retained profit 2022: € 44,681 First fiscal year in the series	€ 63,599 Retained profit 2023: € 63,599 ▲ 42% vs 2022 (€ 44,681) Favourable step	€ 94,262 Retained profit 2024: € 94,262 ▲ 48% vs 2023 (€ 63,599) Favourable step	€ 136,204 Retained profit 2025: € 136,204 ▲ 44% vs 2024 (€ 94,262) Favourable step	▲ 44%
Dividend	€ 10,041 Dividend 2022: € 10,041 First fiscal year in the series	€ 6,117 Dividend 2023: € 6,117 ▼ 39% vs 2022 (€ 10,041) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 6,117) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 49,151 Bank debt 2022: € 49,151 First fiscal year in the series	€ 31,206 Bank debt 2023: € 31,206 ▼ 37% vs 2022 (€ 49,151) Favourable step	€ 12,190 Bank debt 2024: € 12,190 ▼ 61% vs 2023 (€ 31,206) Favourable step	€ 128 Bank debt 2025: € 128 ▼ 99% vs 2024 (€ 12,190) Favourable step	▼ 99%
Balance sheet total	€ 130,712 Balance sheet total 2022: € 130,712 First fiscal year in the series	€ 138,439 Balance sheet total 2023: € 138,439 ▲ 6% vs 2022 (€ 130,712) Unchanged	€ 127,118 Balance sheet total 2024: € 127,118 ▼ 8% vs 2023 (€ 138,439) Unchanged	€ 156,594 Balance sheet total 2025: € 156,594 ▲ 23% vs 2024 (€ 127,118) Unchanged	▲ 23%

Key figures of DUVAL PHARMACEUTICS CONSULTING, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to DUVAL PHARMACEUTICS CONSULTING?

What happened at DUVAL PHARMACEUTICS CONSULTING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 29, 2026 New annual accounts for financial year 2025: profit of € 41,941 (▲ 37% vs 2024). Source: NBB ↗
Jan 26, 2005 Start of the company according to the CBE. KBO
Jan 24, 2005 New establishment in Antwerpen. KBO
2005 Didier Duval became a director. NBB

In short

From € 6,916 profit in 2022 to € 41,941 profit in 2025.

Paid € 58,616 in corporate taxes since 2022.

Best year ever: 2025, with € 41,941 profit.

Paid out € 16,158 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DUVAL PHARMACEUTICS CONSULTING? We notify you, reason included.

Follow DUVAL PHARMACEUTICS CONSULTING

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Didier Duval

DUVAL PHARMACEUTICS CONSULTING

Behind DUVAL PHARMACEUTICS CONSULTING is Didier Duval.

See the full network in the app

Directors

According to the 2025 annual accounts

Didier Duval

Director

since 2005

Establishments

Establishment units

Physical locations of this company

Registered office

Schoolstraat 6

2240 Zandhoven

2.145.277.338

Heistraat 261

2610 Antwerpen

Active since 24 January 2005

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0871.467.004

VAT number

BE 0871.467.004

Registered office

Schoolstraat 6, 2240 Zandhoven

Names & denominations

DUVAL PHARMACEUTICS CONSULTING · DUPHARCO

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

26 January 2005

Peppol

Active · Active since 23 May 2025

Activities · NACE

Activiteiten op het gebied van voeding

Overige activiteiten i.v.m. gezondheidszorg, n.e.g.

Overige menselijke gezondheidszorg, n.e.g.

Overige zakelijke dienstverlening, neg

Overige zakelijke dienstverlening, n.e.g.

View on CBE Public ↗ Annual accounts (NBB) ↗